retatrutide and nad+ together Retatrutide, an experimental weight-loss drug,

Methods Using a subset of Truveta Data, we identified patients who had a prescription for a GLP-1 RA between June 2021 and December 2024

No more wasting food or feeling guilty about not finishing my plate

For most people, however, the duration of action is shorter

The rising prevalence of type 2 diabetes and obesity, innovations such as oral formulations and long-acting drugs, increased patient awareness, and regulatory approvals drive the GLP-1 Analogues market

Research shows that many patients regain weight after discontinuing GLP-1 therapy, which raises questions about whether insurance should cover indefinite use